Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine

Noninvasive drug biomarkers for the early assessment of tumor response can enable adaptive therapeutic decision-making and proof-of-concept studies for investigational drugs. Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and has been shown to be detectable in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2017-08, Vol.23 (16), p.4716-4723
Hauptverfasser:	Husain, Hatim, Melnikova, Vladislava O, Kosco, Karena, Woodward, Brian, More, Soham, Pingle, Sandeep C, Weihe, Elizabeth, Park, Ben Ho, Tewari, Muneesh, Erlander, Mark G, Cohen, Ezra, Lippman, Scott M, Kurzrock, Razelle
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides Aged Aniline Compounds Apoptosis Apoptosis - drug effects Apoptosis - genetics Biomarkers Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - urine Circulating Tumor DNA - genetics Circulating Tumor DNA - urine Decision making Deoxyribonucleic acid DNA DNA, Neoplasm - genetics DNA, Neoplasm - urine Drug development Drug Monitoring Drug Resistance, Neoplasm - genetics Drugs Enzyme inhibitors Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Exons - genetics Experimental design Humans Kinetics Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - urine Lysis Middle Aged Molecular Targeted Therapy Monitoring Mutation Non-small cell lung carcinoma Patients Piperazines - therapeutic use Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Therapy Time Factors Treatment Outcome Tyrosine Urine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!